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Abstract: Modern tools of genomics and proteomics reveal potential therapeutic antisense 
targets in asthma, increasing the interest in the development of anti-mRNA drugs. In allergic 
asthma experimental models, antisense oligonucleotides (ASO) are administered by inhalation 
or systemically. ASO can be used for a large number of molecular targets: cell membrane recep-
tors (G-protein coupled receptors, cytokine and chemokine receptors), membrane proteins, ion 
channels, cytokines and related factors, signaling non-receptor protein kinases (tyrosine kinases, 
and serine/threonine kinases) and regulators of transcription belonging to Cys4 zinc ﬁ  nger of 
nuclear receptor type or beta-scaffold factors with minor groove contacts classes/superclasses 
of transcription factors. A respirable ASO against the adenosine A1 receptor was investigated 
in human trials. RNase P-associated external guide sequence (EGS) delivered into pulmonary 
tissues represents a potentially new therapeutic approach in asthma as well as ribozyme strate-
gies. Small interfering RNA (siRNA) targeting key molecules involved in the patho-physiology 
of allergic asthma are expected to be of beneﬁ  t as RNAi immunotherapy. Antagomirs, synthetic 
analogs of microRNA (miRNA), have important roles in regulation of gene expression in asthma. 
RNA interference (RNAi) technologies offer higher efﬁ  ciency in suppressing the expression of 
speciﬁ  c genes, compared with traditional antisense approaches.
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Introduction
Asthma is one of the most common chronic diseases, throughout the world being 
estimated at around three hundred million asthmatic persons. Global Initiative for 
Asthma guidelines are currently revised. These international recommendations are 
based on scientiﬁ  c evidence elicited from therapeutic interventions (Bousquet et al 
2007), and periodic assessment of asthma control is considered more relevant and use-
ful (Humbert et al 2007). Asthma is a complex chronic inﬂ  ammatory disorder of the 
airways, usually allergic, characterized at molecular level by upregulated expression 
of genes encoding multiple inﬂ  ammatory proteins, such as cytokines and chemokines, 
adhesion molecules, mediator-synthesizing enzymes, proinﬂ  ammatory receptors, and 
dysregulated apoptosis in some inﬂ  ammatory cells.
The mechanism of action for conventional asthma drugs usually involves binding 
to different proteins or interfering with their activity, these therapies only temporar-
ily preventing targeted protein function. Standard asthma treatments can be classiﬁ  ed 
as controllers and relievers. Relievers are drugs used on an as-needed basis that 
reverse bronchoconstriction and relieve its symptoms (rapid acting inhaled selective 
beta2-agonists). Controllers are drugs taken on a long-term basis to keep asthma 
under clinical control mainly through their anti-inﬂ  ammatory effects (glucocortico-
steroids, antileucotrienes). Inhaled corticosteroids are the most effective controller 
drugs currently available. These drugs with potent anti-inﬂ  ammatory effects can be 
regarded as agonists of Cys4 zinc ﬁ  nger transcription factors because they activate Biologics: Targets & Therapy 2007:1(3) 272
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the glucocorticoid receptor for the direct or indirect regulation 
of expression of target genes (Popescu 2005).
Although there is no cure for persistent asthma, appropri-
ate management often results in the achievement of control, 
but requires daily medication, which may reduce compliance. 
Moreover, current therapies fail to restore the immunologi-
cal imbalance, frequently do not produce an optimal control 
of asthma symptoms, and sometimes are associated with 
adverse effects.
Despite signiﬁ  cant advances that have been made in recent 
years, there is still an urgent need for novel, more effective 
and safer asthma drugs. An important objective in molecular 
pharmacology is the manipulation of gene expression with 
new drug molecules. RNA-based gene silencing strategies 
have been proposed not only as research tools, but also as 
potential therapeutic interventions in allergic asthma.
Post-transcriptional inhibition of gene expression at the 
mRNA level can be accomplished using antisense oligo-
nucleotides (ASO), DNAzymes, ribozymes (RZ), RNase 
P-associated EGS molecules (EGS), and, more recently, inter-
ference RNA (RNAi) manipulation, including small interfer-
ing RNA (siRNA). Concerted efforts from both academia 
and research-driven pharmaceutical companies have made 
signiﬁ  cant progress in turning these nucleic acid drugs into 
therapeutics (Mahato et al 2005; Pan and Clawson 2006).
A review of the studies regarding antisense approaches 
in asthma is important as an integrated framework for the 
patho-physiological rationale and potential clinical applica-
tion of biologic anti-mRNA agents. Animal models of allergic 
asthma, especially those involving rodents and nonhuman 
primates, are necessary for the development of such therapies 
(Isenberg-Feig et al 2003). Mouse, guinea pig and rat asthma 
models are still used in many experiments. Disadvantages must 
be considered, including difﬁ  culties related to the techniques 
for measuring pulmonary function, and species differences in 
expression or responses to pro-inﬂ  ammatory mediators. Large 
mammal models of allergic asthma have been developed in 
rabbits, dogs, cats, sheep, monkeys (rhesus and cynomolgus), 
primate models being much closer to human persistent asthma. 
Antisense therapies with nucleic acids that speciﬁ  cally target 
the human immune system are not properly active in animals 
less genetically similar to man (Coffman and Hessel 2005). 
Accelerated characterization of asthma-relevant molecular 
targets created increasing interest in the development of anti-
sense agents, that could signiﬁ  cantly reduce the duration of 
an anti-asthma drug development process.
The modern tools of genomics and proteomics reveal 
potential therapeutic antisense targets: membrane and 
intracellular receptors, channels, transporters, enzymes, a 
multitude of factors and regulators (cytokines, chemokines, 
growth factors, transcription factors etc), structural pro-
teins, and nucleic acids etc. Theoretically, any protein can 
be targeted for antisense intervention. Although receptors 
and cytokines are frequently chosen targets for anti-mRNA 
agents, various classes of signal transduction molecules are 
also paid special attention (Popescu 2005a).
Biological targets for new therapeutic interventions in 
asthma must have some characteristics: critical and prefer-
ably unreplaceable roles in asthma pathogenesis, a certain 
level of functional and structural novelty to allow drug speci-
ﬁ  city, insigniﬁ  cant involvement in other important biological 
processes (in order to limit potentially serious side effects), 
a constrained level expression or tissue selectivity to allow 
sufﬁ  cient drug efﬁ  cacy (Zheng et al 2006).
Antisense oligonucleotides (ASO)
ASO are short single-stranded synthetic nucleic acid poly-
mers, consisting of 15–25 nucleotides, that induce the inhi-
bition of target gene expression by exploiting their ability 
to bind to the target messenger RNA (mRNA) by Watson-
Crick base-pairing. The antisense effects (sequence-speciﬁ  c 
effects) of ASO are mainly due to the hybridization with the 
target mRNA in a sequence-dependent complementary man-
ner (binding is performed via hydrogen bonds).
First generation ASO have a phosphorothioate backbone 
modification with replacement of non-bridging oxygen 
atoms in the phophodiester bond substituted by sulfur, in 
order to increase resistance to nucleases. The most important 
mechanism of action of phosphorothioate ASO is the 
activation of RNase H, which cleaves the RNA moiety of 
a DNA-RNA heteroduplex, leading to the degradation of 
the targeted mRNA, and thus preventing translation of the 
speciﬁ  c protein. ASO binding to mRNA can also inhibit 
translation by steric blockade of the ribosome (inhibition of 
the ribosomal complex formation) or interfere with mRNA 
maturation by inhibiting RNA splicing (Kurreck 2003; Chan 
et al 2006; Ulanova, Schreiber, et al 2006).
A disadvantage of phosphorothioate ASO is their binding 
to the basic ﬁ  broblast growth factor (a member of the hepa-
rin-binding family of growth factors), inhibiting its binding 
to cell surface receptors, and removing it from low afﬁ  nity 
binding sites on extracellular matrix (Guvakova et al 1995). 
Such mechanisms may be involved in some adverse effects 
of systemic ASO delivery (Ulanova, Schreiber, et al 2006). 
A dose-limiting toxicity aspect is represented by reversible 
thrombocytopenia related to the phosphorothioate backbone Biologics: Targets & Therapy 2007:1(3) 273
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(Cotter 1999). Hypotension associated with complement 
activation, which can result due to binding to various proteins 
and the polyanionic nature of ASO (Ulanova, Schreiber et al 
2006), are possible in primates (Sereni et al 1999).
Immunostimulatory unmethylated deoxycytosine-
deoxyguanosine (CpG) motifs are normally undesirable as 
they can stimulate Toll-like receptor 9 (TLR9) on several 
cell types, and produce Th1-like proinﬂ  ammatory cytokine 
release, with fever and ﬂ  u-like syndrome (Klinman 2004). 
Many phosphorothioate ASO contain CpG dinucleotides, 
and their position and the sequences ﬂ  anking play critical 
role in determining immunostimulatory activity (Agrawal 
and Kandimalla 2004). Hepatotoxicity may be also related 
to CpG motifs. Non-speciﬁ  c biological effects are possible 
results of four contiguous guanine residues, the guanine 
quartets (Ulanova, Schreiber et al 2006).
Second generation ASO contain nucleotides with alkyl 
modiﬁ  cations at the 2′ position of the ribose. 2′-O-methoxyethyl-
oligonucleotides (2′MOE-ASO) have increased binding 
afﬁ  nity to mRNA and resistance to degradation. Because 
they do not recruit RNase H, the antisense effect can be due 
to the steric blockade of translation. Non-CpG-containing 
2′MOE-ASO have a lower proinﬂ  ammatory risk, indepen-
dent of TLR9 (Senn et al 2005).
Other compounds with alternative structures form a third 
generation of ASO, including peptide nucleic acids, mor-
pholino oligonucleotides, locked nucleic acids, etc (Kurreck 
2003). Because of low cell penetrance of many of these new 
generation ASO, ﬁ  rst generation representatives are still 
commonly used (Ulanova, Schreiber et al 2006). Recently, 
two different conﬁ  gurations of chimeric ASO (altimers and 
gapmers) containing 2′-deoxy-2′-ﬂ  uoro-β-D-arabinonucleic 
acid (FANA) were found to have potent antisense activity 
(Ferrari et al 2006).
In experiments with ASO, there is a need of differen-
tiation between the desired sequence-speciﬁ  c inhibition of 
the targeted mRNA from the undesired sequence-related 
and non-sequence-related effects. Negative controls serve 
to rule out the possibility that ASO effects are caused by 
non-sequence-speciﬁ  c mechanisms, while positive controls 
provide additional evidence that a true antisense effect is the 
reason for the biological effects. A combination of controls is 
recommended. Sense controls are oligonucleotides having a 
sequence complementary to that of the ASO (identical to the 
mRNA target), while reverse controls are obtained by revers-
ing the antisense sequence with respect of its 5′–3′ orientation. 
Random (nonsense or scrambled) controls are generated by 
mixing up the ASO bases in a randomized manner, while 
mismatch controls are obtained by the deliberate introduc-
tion of one or more mismatches into the antisense sequence 
(Brysch 2000).
The pharmacokinetics of ASO depends on the system 
and mode of delivery. First generation ASO bind to plasma 
proteins after systemic administration, ensuring a prolonged 
effect. Local delivery of ASO to the airways (respirable ASO) 
is effective at smaller doses compared with other routes of 
administration. ASO delivered as aerosols directly to the 
lungs, minimize the potential for non-antisense systemic 
side effects and toxicity (Tanaka and Nice 2001). In vivo 
absorption, tissue distribution, metabolism and excretion, 
efﬁ  cacy and safety studies of respirable ASO suggest that 
these antisense agents can be safely delivered to target 
respiratory tissues in low, but effective doses (Ali et al 2001; 
Sandrasagra et al 2002; Popescu 2003).
Enhancing the delivery of ASO molecules to cells is an 
essential issue for antisense therapeutics. Potential adverse 
effects may also be related to ASO delivery systems. Cationic 
liposome formulations, used as transmembrane carriers, 
enhance immunostimulatory properties of ASO with systemic 
pro-inﬂ  ammatory cytokine release and may affect cellular 
functions directly (Ulanova, Schreiber et al 2006), by inhib-
iting TNF-alpha-induced endothelial vascular cell adhesion 
molecule-1 (VCAM-1) expression in human pulmonary artery 
endothelial cells (Maus et al 1999). Although not as potent 
in vitro as cationic lipid systems, cell-penetrating peptides-
oligonucleotide conjugates may have substantial advantages 
in vivo over particle-based delivery (Juliano 2006).
In the treatment of allergic asthma, ASO can be used 
for silencing of gene expression, at post-transcriptional 
level, for many molecular targets: cell membrane recep-
tors (G-protein coupled receptors, cytokine and chemokine 
receptors), membrane proteins, ion channels, cytokines and 
related factors (Table 1), signaling non-receptor protein 
kinases (tyrosine kinases, such as Syk, and serine/theonine 
kinases, such as p38 MAP kinase) and regulators of tran-
scription belonging to Cys4 zinc ﬁ  nger of nuclear receptor 
type (GATA-3) or beta-scaffold factors with minor groove 
contacts (p65, STAT-6) classes/superclasses of transcription 
factors (Table 2) (Popescu 2005a).
Aerosolized adenosine A1 receptor ASO (EPI-2010) is 
a respirable phosphorothioate ASO targeting adenosine A1 
receptor (AA1R) abnormally overexpressed in the allergic 
lung (Ali et al 2001). The gene ADORA1 located on chro-
mosome 1q32.1 encodes AA1R that belongs to the G-protein 
coupled receptor 1 family. AA1R ASO reduced adenosine 
A1 receptors number in bronchial smooth muscle cells, and Biologics: Targets & Therapy 2007:1(3) 274
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preclinical studies in rabbits and primates revealed that EPI-
2010 attenuates adenosine- and allergen-induced bronchial 
obstruction. The ability of EPI-2010 to block airway hyperre-
sponsiveness (AHR) to inhaled adenosine persisted for several 
days, giving it the potential to be a once-per-week treatment 
for asthma (at the time of phase I clinical trials). The effect 
on the inﬂ  ammatory markers from bronchoalveolar lavage 
(BAL) and lung immunohistopathology were not reported. 
A single effective dose was 50 μg/kg and the effect duration 
was of almost 7 days (Tanaka and Nyce 2001). EPI-2010 was 
safe and well tolerated, but Phase IIa clinical trials revealed 
modest data of efﬁ  cacy in patients with mild asthma (Ball 
et al 2003; 2004). The evidence suggests that the treatment 
with AA1R ASO failed to conﬁ  rm the anticipated effective-
ness because the pathophysiology of allergic asthma is far 
more complex, involving a large number of immunological 
changes, not only a single receptor with proinﬂ  ammatory and 
bronchoconstrictive actions (Popescu 2005a).
Interleukin-5 (IL-5) is critical for producing speciﬁ  c 
tissue eosinophilia in allergic asthma. IL-5 receptor alpha 
chain (IL-5R-alpha, CD125) is encoded by the gene IL5RA 
(3p26–p24). ASO against IL-5R-alpha is a 2′MOE-type that 
decreased in vitro mRNA and protein expression, and in vivo 
inhibited the development of blood and tissue eosinophilia, in 
a ragweed-induced allergic peritonitis murine model (Lach-
Triﬁ  lieff et al 2001). GM-CSF/IL-3/IL-5 receptor common 
beta-chain (CD131) is encoded by CSF2RB (22q12.2–q13.1). 
GM-CSF/IL-3/IL-5 R-beta ASO (AS143), a phosphorothio-
ate ASO administered intratracheally in a rat allergic asthma 
model, reduced lung beta chain of IL-3/IL-5/GM-CSF mRNA 
and protein expression, and inhibited antigen-induced lung 
eosinophilia and AHR to LTD4 (Allakhverdi et al 2002).
C-C chemokine receptor type 3 (CCR-3) is the main 
chemokine receptor involved in eosinophil attraction into 
airway inﬂ  ammation in asthma. A multitargeted approach 
with the blocking of multiple inflammatory pathways 
Table 1 ASO targeting cell surface receptors, membrane proteins, ion channels, cytokines and related factors in allergic asthma
Molecular target   Gene name   ASO route of administration
of ASO-based therapy  [chromosomal location]  in the experimental model (reference)
Adenosine A1 receptor   ADORA1  AA1R ASO – inhalation
(AA1R)  [1q32.1]  house-dust mite-sensitized rabbits, 
     Ascaris-sensitized primate asthma models,
      humans with asthma (Nyce 2002)
IL-5 receptor alpha chain   IL5RA  IL-5R-alpha ASO – intravenous
(IL-5R-alpha, CD125)   [3p26–p24]  ragweed-induced allergic peritonitis murine model 
     (Lach-Triﬁ  lieff et al 2001)
GM-CSF/IL-3/IL-5 receptor  CSF2RB  GM-CSF/IL-3/IL-5 R-beta ASO – intratracheal 
common beta-chain (CD131)  [22q12.2–q13.1]  rat allergic asthma model (Allakhverdi et al 2002)
C-C chemokine receptor type3  CCR3  CCR-3 ASO (ASA4) – intratracheal
(CCR-3)  [3p21.3]  simultaneously with GM-CSF/IL-3/IL-5 R-beta 
      ASO rat allergic asthma model (Allakhverdi 2006)
alpha-4 subunit of VLA-4 receptor  ITGA4  CD49d ASO (ISIS 107248) – inhalation
(CD49d)   [7p12.3–p12.1]  OVA-challenged mouse lung (Lofthouse et al 2005)
CD86  CD86 gene  CD86 ASO – inhalation
(B7-2)  [3q21]  OVA-induced mouse model of asthma 
      (Crosby et al 2007)
Gob-5   CLCA1  Gob-5 ASO – intratracheal (adenoviral vector) 
(Ca2+-dependent chloride channel-1)  [1p31–p22]  mouse model of asthma (Nakanishi et al 2001)
interleukin 4  IL4  IL-4 ASO 
(IL-4)  [5q23–q31]  treated CD4+ cells from OVA-sensitized rats, 
      administered intraperitoneally to naive rats
      challenged later with OVA aerosol (Molet et al 1999)
interleukin 5  IL5  IL-5 ASO (ISIS 20391) – intravenous 
(IL-5)  [5q23–q31]  murine OVA-induced asthma and allergic peritonitis
      model (Karras et al 2000)
Kit ligand/stem cell factor   KITLG  SCF ASO – intranasal 
(SCF)   [12q22]  OVA-sensitized mice with asthma (Finotto et al 2001a)
Tumor necrosis factor-alpha   TNFA  TNF-alpha AS-ON (ISIS 104838) – inhalation
(TNF-alpha)   [6p21.3]  mouse model of chronic asthma (Crosby et al 2005)
Abbreviations: ASO, antisense oligonucleotide; OVA, ovalbumin;   VLA-4, very late antigen-4; OVA, ovalbumin. Biologics: Targets & Therapy 2007:1(3) 275
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achieved by simultaneously intratracheal administration of 
two ASO, AS143 and CCR-3 ASO (ASA4), in sensitized 
Brown Norway rats, resulted in fewer eosinophils detected 
in BAL of animals treated with both ASO as compared to 
each ASO alone, and AHR to LTD4 signiﬁ  cantly decreased 
at lower doses in the two ASO-treated groups versus to a 
single ASO (Allakhverdi et al 2006).
VLA-4 (very late antigen-4) is the alpha4beta1 integrin 
localized on many inﬂ  ammatory cells that participates in 
cell adhesion, trafﬁ  cking and activation, through binding to 
VCAM-1 and ﬁ  bronectin. Small molecule VLA-4 inhibitors 
have demonstrated inhibition of AHR and lung inﬂ  ammation 
in animal asthma models. The VLA-4 alpha subunit (CD49d) 
may be target for second generation ASO (ISIS 107248), 
also known as ATL-1102. Loe dose of 2′MOE-ASO deliv-
ered by inhalation in ovalbumin (OVA)-challenged mouse 
lung inhibited allergen-induced eosinophil lung inﬁ  ltration, 
mucus production, and AHR to methacholine (Lofthouse 
et al 2005).
Inhaled CD86 ASO may have utility in asthma treatment. 
The B7-family molecule CD86, expressed on the surface of 
pulmonary antigen presenting cells, is a type I membrane pro-
tein that is a member of the immunoglobulin superfamily. The 
CD86 gene is located on chromosome 3q21. CD86–CD28 
signaling is involved in priming allergen-speciﬁ  c T cells. 
In an OVA-induced mouse model of asthma, inhaled aero-
solized CD86 ASO suppressed OVA-induced up-regulation 
of CD86 protein expression on pulmonary dendritic cells, 
macrophages and recruited eosinophils, correlated with 
decreased methacholine-induced AHR, pulmonary inﬂ  am-
mation, mucus production and BAL eotaxin levels (Crosby 
et al 2007).
Gob-5, a member of Ca2+-dependent chloride channel 
family (gene CLCA1 on chromosome 1p31–p22) is an impor-
tant molecule in murine asthma. Intratracheal administration 
of adenovirus-expressing antisense gob-5 RNA in a mice 
model of asthma inhibited gob-5 expression, prevented goblet 
cell hyperplasia, decreased AHR and mucus overproduction 
(Nakanishi et al 2001).
Interleukin-4 (IL-4) has important pro-inﬂ  ammatory 
actions in asthma including induction of the IgE isotype 
switching, expression of VCAM-1, increase production of 
eotaxin by ﬁ  broblasts, epithelial and endothelial cells, and 
differentiation of Th2 lymphocytes. The IL-4 receptor alpha 
chain plays special roles in allergy, being a common subunit 
of the IL-4 and IL-13 receptor complex. Signaling through 
it by IL-4 is important in Th2 differentiation, and the block-
ing of its production inhibits the activity of IL-4 and IL-13, 
regulating allergic inﬂ  ammation, mucus overproduction, 
and AHR. The IL-4 receptor alpha chain was studied as a 
target for new inhaled second generation ASO (ISIS 369645) 
(Popescu 2005).
IL-4 ASO treated CD4+ cells from OVA-sensitized rats, 
transferred to naive rats, decreased IL-4 expression, inhib-
ited the adoptively transferred late phase allergic response 
in a dose related manner (Molet et al 1999). Genes IL4 and 
IL5 are located on chromosome 5q23–q31. IL-5 ASO, a 
2′MOE-ASO (ISIS 20391), administered intravenously in 
a murine OVA-induced asthma and an allergic peritonitis 
model, inhibited IL-5 mRNA and IL-5 protein expression, 
reduced antigen-induced lung eosinophilia and inhibited the 
late phase AHR (Karras et al 2000).
The Kit ligand or stem cell factor (SCF) acts as an impor-
tant growth factor for human mast cells, induces chemotaxis 
Table 2 ASO targeting non-receptor protein kinases and transcription factors in allergy
Molecular target   Gene name   ASO route of administration 
of ASO-based therapy  [chromosomal location]  in the experimental model (reference)
Spleen tyrosine kinase  SYK  Syk ASO – inhalation (ASO:liposome complexes)
(Syk)  [9q22]  infectious model of airway inﬂ  ammation induced by
   Nippostrongylus brasiliensis larvae and IgE-mediated
    OVA-induced asthma in rat (Stenton et al 2000; 
    2002; Ulanova et al 2003)
Mitogen-activated protein kinase 14   MAPK14   p38 alpha MAPK ASO (ISIS 101757)
(p38 alpha MAP kinase)  [6p21.3–p21.2]  – inhalation or nose-only exposure OVA-
    sensitized mice with asthma (Duan et al 2005)
p65 subunit of NF-kB  RELA  p65 ASO – intravenous OVA-sensitized
(p65 subunit nuclear factor NF-kappaB)  [11q13]  mice with asthma (Choi et al 2004)
GATA-3 GATA3  GATA-3  ASO  –  intranasal 
(a T-cell speciﬁ  c transcription factor)   [10p15]  OVA-sensitized murine model of asthma
      (Finotto et al 2001b)
Abbreviations: ASO, antisense oligonucleotide; OVA, ovalbumin; MAP kinase, mitogen-activated protein kinase.Biologics: Targets & Therapy 2007:1(3) 276
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and survival of the mast cell and enhances antigen-induced 
degranulation of human lung-derived mast cells. SCF gene, 
KITLG, is located on chromosome 12q22. SCF ASO, a 
ﬂ  uorescein isothiocyanate-labeled phosphorothioate ASO, 
delivered in OVA-sensitized mice with asthma, inhibited 
SCF expression in interstitial lung cells, reduced IL-4 
concentration in the BAL ﬂ  uid, decreased eosinophil and 
mast cell counts in lung interstitial tissue and/or BAL ﬂ  uid, 
as effective as a corticosteroid treatment (Finotto, Buerke, 
et al 2001).
TNF-alpha (tumor necrosis factor-alpha) is involved as 
a causative factor of allergic asthma inﬂ  ammation, being a 
cytokine involved in many effects associated with airway 
epithelium (alteration of permeability, up-regulation of 
ICAM-1 expression, stimulation of IL-6, IL-8 and GM-CSF 
production) and other relevant effects in the lungs. TNF-alpha 
ASO (ISIS 104838), a 2′MOE-ASO, delivered by inhalation 
in a mouse model of chronic asthma, reduced TNF-alpha 
protein in BAL ﬂ  uid, inhibited recruitment of eosinophils and 
neutrophils to the airways, decreased lung inﬂ  ammation, and 
reduced mucus production and AHR (Crosby et al 2005).
Lyn is a member of the Src family of nonreceptor tyro-
sine-protein kinases that is expressed in the hemopoietic cells 
in asthmatic airway inﬂ  ammation (with the exception of T 
lymphocytes). Lyn is implicated in many signaling pathways, 
including those for IgE, IL-5 and other cytokines and growth 
factors. However, the role of Lyn in asthma is controversial. 
Lyn ASO experiments with puriﬁ  ed eosinophils and OVA-
sensitized murine bone marrow cells, revealed that this ASO 
kinase blocked Lyn expression in eosinophils, prevented IL-5 
receptor cascade activation and inhibited eosinophil differen-
tiation from stem cells, attenuated antiapoptotic IL-5 effect 
on eosinophils, similarly to Raf-1 ASO, which in contrast 
inhibited also eosinophil cationic protein (ECP) secretion 
(Pazdrak et al 1998; Stafford et al 2002). Recently, it was 
reported that Lyn-deﬁ  cient mice develop severe, persistent 
asthma, Lyn being a negative regulator of Th2 immunity 
(Beavitt et al 2005).
The spleen tyrosine kinase (Syk) is an interesting new 
therapeutic approach in allergic asthma. This non-receptor 
tyrosine-protein kinase (Ulanova et al 2003) plays a wide 
role in the regulation of immune and inﬂ  ammatory responses 
(Duta et al 2006), being involved in immunoreceptor sig-
nalling complexes in leukocytes, and in various signalling 
cascades including those originating from integrin and cyto-
kine receptors (Ulanova et al 2005). A 60 base pairs ASO 
constructed as a stem-loop structure and containing three 
phosphorotioate modiﬁ  cations, for speciﬁ  c inhibition of Syk, 
was constructed. Syk ASO was delivered in vivo as aerosols 
using liposome complexes combining cationic 1,2-dioleoyl-
3-trimethylammonium-propane (DOTAP) with a neutral 
carrier lipid, dioleoylphosphatidyl-ethanol-amine (DOPE). 
DOTAP-DOPE liposomes form complexes with ASO at a 
2.5:1 ratio (Stenton et al 2000). Two animal models were 
used, an infectious model of airway inﬂ  ammation induced 
by the helminth Nippostrongylus brasiliensis larvae and an 
IgE-mediated OVA-induced asthma in Brown Norway rats. 
Syk ASO reduced Syk mRNA and protein expression in 
inﬂ  ammatory cells, depressed up-regulation of some adhesion 
molecules (ICAM-1, alpha4 and beta2 integrins), suppressed 
antigen-mediated trachea contraction, inhibited nitric oxide 
and TNF release from alveolar macrophages and antigen-
induced pulmonary inﬂ  ammatory cell inﬁ  ltrate, decreasing 
eosinophilia and neutrophilia (Stenton et al 2002). Although 
Syk ASO signiﬁ  cantly reduced lung inﬂ  ammatory responses 
in experimental asthma and acute lung injury models, long 
term delivery must be further assessed (Ulanova, Schreiber, 
et al 2006).
p38 MAP kinase is a non-receptor proline-directed 
serine/threonine kinase with a pivotal role in the activation 
of inﬂ  ammatory cells. p38 alpha MAP kinase ASO (ISIS 
101757) is a 2′MOE-ASO delivered as aerosol for inhalation 
or nose-only exposure, in OVA-sensitized mice with asthma. 
It inhibited p38 alpha mRNA and protein expression in BAL 
ﬂ  uid cells and peribronchial lymph node cells, reduced mucus 
hypersecretion, suppressed Th2 cytokine production (IL-4, 
IL-5 and IL-13 levels in BAL ﬂ  uid), and inhibited airway 
eosinophilia and AHR (Duan et al 2005).
The transcription factor, nuclear factor NF-kappaB 
(NF-κB) transactivates various genes for proinﬂ  ammatory 
cytokines and many other immunoregulatory genes, having 
a important role in the regulation of airway inﬂ  ammatory 
process in asthma. In most cells, the NF-κB prototype is a 
heterodimer composed of a 50 kDa (p50) and 65 kDa (p65) 
polypeptides. The p65 subunit is responsible for the strong 
transcription activating potential of NF-κB. Mice sensitized 
and challenged with OVA were intravenously administered 
p65 ASO. This supressed the allergen-speciﬁ  c IgE response, 
reduced eosinophil number, TNF-alpha and Th2 cytokines, 
IL-4 and IL-5, in BAL ﬂ  uid, and inhibited eosinophilic 
inﬁ  ltration and AHR (Choi et al 2004).
GATA-3, a trans-acting T-cell speciﬁ  c transcription 
factor, encoded by the gene GATA3 (10p15), has a critical 
role in Th2 differentiation (IL-4 dependent and IL-4 inde-
pendent) and in Th2 cell proliferation. GATA-3 is identiﬁ  ed 
as a cell lineage-speciﬁ  c transcription factor selectively Biologics: Targets & Therapy 2007:1(3) 277
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expressed and activated in the Th2 lineage as a conse-
quence of STAT-6 activation (Finotto and Glimcher 2004). 
EPI-30051 is a respirable ASO targeting GATA-3 transcrip-
tion factor (Paterson 2001, Popescu 2005b). GATA-3 ASO, 
synthesized with a phosphorothioate backbone to improve 
resistance to endonucleases, has the potential advantage of 
simultaneously down-regulation of various Th2 cytokines 
expression, rather than suppressing a single mediator. A 
ﬂ  uorescein isothiocyanate-labeled GATA-3 ASO delivered 
intranasal in an OVA-sensitized murine model of asthma, 
reduced intracellular GATA-3 lung expression due to DNA 
uptake in lung cells, suppressed Th2 cytokine production, 
and inhibited eosinophilic inﬁ  ltration and AHR (Finotto, 
De Sanctis et al 2001).
The new ASO of a ribbon type (RiASO) consist of two 
loops containing multiple antisense sequences and a stem 
connecting the two loops. Three antisense sequences targeting 
different binding sites are placed in a loop (Moon et al 2000). 
Ri-ASO for TGF-beta1 was recently developed (Choi et al 
2005). RiASO are more stable against nucleases (Moon et al 
2000) and may be used for developing antisense drugs.
A different strategy to inhibit target gene expression 
based on DNA technology is represented by decoy oligo-
deoxynucleotides (ODN). These agents are short double-
stranded synthetic ODN molecules that contain transcription 
factor binding sites which are highly useful in transcriptional 
regulation. Delivered into cells, decoy ODN agents bind to 
nuclear transcription factors, preventing their binding to 
consensus sequences in target genes. Decoy ODN with a 
circular dumbbell structure were also developed in order 
to exhibit higher resistance to nucleases (Lee et al 2003; 
Gambari 2004).
Decoy ODN speciﬁ  c for transcription factor STAT-1 
inhibits allergen-induced airway inﬂ  amamtion and airway 
hyperreactivity in a murine model of asthma (Quarcoo et al 
2004). Experiments performed in vitro revealed targeted 
disruption of STAT-6 DNA binding activity by a decoy ODN 
blocks IL-4-driven Th2 cell response (Wang et al 2000) and 
abolishing of induced IL-5 gene expression by a GATA-3 
decoy ODN (Nakamura and Hoshino 2005).
Locations of previously discussed susceptibility genes for 
asthma, as well as associated phenotypes such as bronchial 
hyperresponsiveness and atopy, have been identiﬁ  ed by 
genome-wide linkage analysis (Howard et al 2003). Recently 
some candidate genes were identiﬁ  ed by positional cloning: 
ADAM33, a disintegrin and metalloprotease domain 33 
(20p13), AAA1, asthma-associated alternatively spliced 
gene 1 (7p14.3) and NPSR1, neuropeptide S receptor 1, also 
known GPRA, G-protein-coupled for asthma susceptibility 
(7p14.3).
ADAM33 and NPSR1, strong candidates for involve-
ment in asthma pathogenesis, may be also new targets for 
antisense therapy (Ulanova, Schreiber et al 2006). Antisense 
deletion of ADAM33 in human altered airway ﬁ  broblasts 
inhibits the expression of contractile proteins, such as alpha-
actin, induced by TGF-beta and accelerates their apoptosis, 
explaining why this gene is involved in bronchial hyper-
responsiveness and the progression of asthma (Holgate 
et al 2004). Although not every gene relevant to asthma is 
likely to represent a drug target for ASO, some new oligo-
nucleotides have a potential to improve therapeutic beneﬁ  ts 
(Popescu 2005a).
Ribozymes (RZ)
RZ are synthetically engineered, catalytically active RNA 
molecules, capable of cleaving target mRNA (RNA enzymes), 
with high sequence speciﬁ  city. Allergic asthma represents a 
clinical area suitable for RZ use (Popescu 2005a).
The most advanced in therapeutic applications are ham-
merhead RZ, presenting a catalytic core that cleaves any 
NUH triplets (where N can be any ribonucleotide, and H can 
be any ribonucleotide except guanosine), and two helices 
that bind the target mRNA. Hairpin RZs usually cleave after 
BNGUC (where B can be any nucleotide except adenosine). 
A new type of binary hammerhead ribozymes with improved 
catalytic activity and nucleolytic stability was recently 
assessed (Vorobjeva et al 2006).
To date, many protein molecules involved in asthma 
immunopathogenesis have been identiﬁ  ed, and it is antici-
pated that the list will grow. RZ can be used to cleave 
the mRNA encoding such speciﬁ  c targets (Freelove and 
Zheng 2002). Hammerhead and hairpin RZs targeting con-
served sequences within IL-5, NF-κB and ICAM-1 mRNA 
have been already designed. Pharmacokinetic studies in 
mice revealed that intratracheal RZs administration increase 
exposure in lungs (Sandberg et al 2001). Finally, it has to be 
taken into account that RZ may be less effective than RNAi 
in many respects (Li et al 2007).
RNase P-associated external
guide sequence (EGS)
RNA in a complex with another oligoribonucleotide 
known as an external guide sequence (EGS) can become a 
substrate for ribonuclease P (Yuan and Altman 1994). EGS 
technique can be used to cleave target mRNA by forming a 
tRNA-like structure.Biologics: Targets & Therapy 2007:1(3) 278
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Considering that no adverse effects related to the loss 
of IL-4 function were observed in human subjects at pul-
monary level or systemically, an EGS targeting the human 
IL-4 receptor alpha mRNA was recently studied in in vitro 
and tissue cultures. The gene for IL-4 receptor alpha chain 
(IL-4R-alpha, CD124) is IL4R (IL4RA), located on chromo-
some 16p11.2–p12.1.
Based on the similarity to the tRNA cleavage con-
sensus sequence and location in exposed regions of the 
human IL-4 receptor alpha mRNA, the sequence EGS1 was 
designed (Dreyfus et al 2004). This efﬁ  ciently directs RNase 
P-mediated cleavage of mRNA for human IL-4R mRNA. 
Blockade of the IL-4 receptor alpha chain is able to inhibit 
the pathogenic effects of both IL-4 and IL-13 using a single 
antisense agent.
Although no trials of EGS have been reported in human 
or animal models, it is possible that inhaled small nuclease-
resistant EGS delivered into pulmonary tissues using 
endogenous lung surfactants may represent a potential new 
therapeutic approach in asthma. Because of the potential for 
a single EGS to recycle and due to different mechanisms of 
action, involving the ability to act as a co-catalyst for the 
ubiquitous RNase P, inhaled EGS could have advantages over 
conventional ASO. Reduced off-site cleavage by EGS is an 
advantage, not only over conventional ASO, but also relative 
to RNAi (Dreyfus et al 2004). These data suggest that the 
effect of EGS is more rapidly apparent compared with that 
of siRNA (Zhang and Altman 2004). Another advantage is 
represented by the fact that RNase P is ubiquitously present 
in cells, in signiﬁ  cant amounts (Dreyfus et al 2004).
RNA interference (RNAi)
After the discovery of RNA interference and its mechanisms 
(Fire et al 1998; Mello and Conte 2004), it was considered 
that RNAi might be a useful approach in future gene therapy 
(Soutschek et al 2004; Zimmermann et al 2006). RNAi is 
an endogenous gene-silencing mechanism that involves 
double-stranded RNA-mediated sequence-speciﬁ  c mRNA 
degradation. RNAi is an evolutionarily conserved post-
transcriptional RNA-dependent gene silencing mechanism. 
RNAi pathways are guided by small non-coding RNA 
molecules, such as double-stranded small interfering RNA 
(siRNA) and microRNA (miRNA), key regulators of gene 
expression. Both siRNA and miRNA are loaded into the 
RNA-induced silencing complex (RISC) where they guide 
mRNA degradation or translation repression dependent on 
target complementarity (Figure 1 represents a scheme of 
the mechanism of action of antisense therapy strategies). 
RISC may be an attractive target for novel pharmacological 
therapies (Dreyfus 2006).
The RNAi pathway is initiated by the Dicer enzyme, a 
riboendonuclease belonging to the RNase III family, that 
cleaves double-stranded RNA (dsRNA) and pre-miRNA 
into short double-stranded RNA fragments about 20–25 
nucleotides long, usually with a two-base overhang on the 
3′ end. The short RNA fragments are known as siRNA when 
they derive from exogenous sources and miRNA when they 
are produced from pre-miRNA. Processed from pri-miRNA 
by the RNase III Drosha and its partner dsRNA-binding 
protein Pasha, pre-miRNA are stem-loop precursors of 
approximately 70 base pairs transported into the cytoplasm 
by exportin 5.
dsRNA and pre-miRNA are processed in fact by a com-
plex consisting of Dicer, TAR RNA-binding protein (TRBP) 
and protein activator of protein kinase PKR (PACT), facilitat-
ing loading of siRNA or miRNA duplex into Argonaute 2 
(AGO2) and RNA-induced silencing complex (RISC). One 
of the two strands of each fragment, known as the guide 
strand, is then incorporated into the RISC. Argonaute proteins 
are the catalytic components of the RISC, AGO2 cleaving 
the passenger stand (Kim and Rossi 2007).
RNAi regulatory RNA molecules include synthetic 
siRNA, pol III transcribed small hairpin RNA (shRNA), or 
endogenous or artiﬁ  cial miRNA (Scherr and Eder 2007). 
These agents may be delivered by using either viral or 
nonviral vectors. Several animal models of human disease 
have been treated with such nucleic acids eliciting RNAi 
(Marsden 2006).
Advances in the nucleic acid chemistry, formulations and 
methods of delivery have created the possibility to develop 
effective RNAi-based therapeutics (Liu et al 2007). RNAi 
technologies offer higher efﬁ  ciency to suppress the expres-
sion of speciﬁ  c genes, compared with traditional antisense 
approaches (Kurrek 2003; Wadhwa et al 2004; Bagasra and 
Prilliman 2004). Recently, improved targeting of miRNA 
with ASO was described (Davis et al 2006).
Although RNAi appears to be attractive for future 
therapeutics, controlling intracellular shRNA expression 
levels is very important, because oversaturation of cellular 
miRNA/shRNA pathways has been proven to be able to 
induce fatalities in adult mice (Grimm et al 2006).
RNAi triggered by siRNA
Over the last years researchers have put considerable effort 
into developing siRNA for therapeutic purposes (Karagiannis 
and El-Osta 2005). Introduction of siRNA into cells can cause Biologics: Targets & Therapy 2007:1(3) 279
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sequence-speciﬁ  c gene silencing. Difﬁ  culties regarding the 
therapeutic application of siRNA are represented mainly by 
the delivery to the intracellular location in the target cells 
involved in the disease pathogenesis, and interaction with 
the RNAi machinery. In order to ameliorate these problems 
chemical modiﬁ  cations of siRNA, and viral and nonviral 
nucleic acid delivery systems have been developed (Oliveira 
et al 2006). A potential disadvantage of RNAi is represented 
Figure 1 Schematic mechanisms of action of antisense therapeutic strategies.
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by the fact that the expression of RISC must be induced or 
may not be induced in all cell types, and may be saturated 
by multiple mRNA targets (Dreyfus et al 2004).
In a RNAi study, tyrosine-protein kinase Btk (Bruton’s 
tyrosine kinase or Bruton agammaglobulinemia tyrosine 
kinase) was evaluated. Btk is a non-receptor tyrosine kinase 
encoded by the gene BTK (Xq21.3–q22) that plays a vital 
and complex modulatory role in many cellular processes. 
Increased IgE responses and exaggerated airway inﬂ  am-
mation was reported in Btk-deﬁ  cient mice (Kawakami et al 
2006). Btk can transiently be depleted following transfection 
or microinjection of Btk siRNA duplexes, and the induction 
of histamine release mast cells was reduced by 20%–25% 
upon Btk down-regulation (Heinonen et al 2002).
Another molecular target for post-transcriptional silenc-
ing is represented by Ras guanyl nucleotide-releasing protein 
4 (RasGRP4), a mast cell-restricted non-kinase intracellular 
signaling protein, with calcium- and diacylglycerol-binding 
motifs, required for the efﬁ  cient expression of granule prote-
ases in the mast cells. In an in vitro experiment, inhibition of 
RasGRP4 expression was obtained using a siRNA approach 
in a rat mast cell line, targeting RasGRP4 gene (19q13.1). 
siRNA-mediated inhibition of RasGRP4 expression in a 
similar cell line resulted in an inhibition of prostaglandin 
D2 (PGD2) synthase expression. Activated human mast 
cells release PGD2, an eicosanoid mediator involved in the 
pathogenesis of allergic asthma. RasGRP4 regulates the 
expression of PGD2 in human mast cell lines (Li et al 2003). 
Some experts consider that inhibition of histamine or PGD2 
release by mast cells, even mediated by RNAi, could have 
potential unwanted effects (Grzela et al 2004).
NF-κB is an important transcription factor that modulate 
airway inﬂ  ammation in asthma due to its central role in the 
regulation of many immune and inﬂ  ammatory processes, 
therefore it represents an interesting target for siRNA. The 
gene encoding transcription factor NF-κB p65 (nuclear 
factor NF-kappa-B p65 subunit) is RELA (11q13). siRNA 
directed to the p65 subunit of NF-κB (siRNA.p65) delivered 
by transfection in airway epithelial cells decreases levels 
of p65 mRNA and protein, and signiﬁ  cantly inhibits the 
TNF-alpha-induced release of IL-6 and IL-8 (Platz et al 
2005). These data indicate that RNAi has a potential use as 
a targeted therapy toward regulatory factors in the NF-κB 
pathway (Guo et al 2005).
Because ASO for the signal transducer and activator 
of transcription 6 (STAT-6) transfected in human lung 
epithelial or airway smooth muscle cells induce dose-
dependent STAT-6 downregulation and prevent IL-13- and 
IL-4-dependent eotaxin release (Hill et al 1999; Peng et al 
2004), STAT-6 is studied also as a target for siRNA. STAT6 
gene is located on chromosome 12q13 and encodes a Th2 
differentiation transcription factor belonging to the family 
of cytokine-activated, tyrosine-phosphorilated transcription 
factors. STAT6 speciﬁ  c siRNA molecules induce the knock 
down of STAT6, blocking the release of eotaxin-3 in human 
epithelial cells stimulated with IL-4 and TNFalpha, while 
other pathways, such as the EGF stimulated release of IL-8, 
remain active (Rippmann et al 2005).
Recently it has been shown that Syk is widely expressed 
in airway epithelial cells and inhibition of Syk using siRNA 
down-regulated iNOS expression and reduced NO produc-
tion. This effect appeared stimulated via beta1-integrins. 
Inhibition of Syk down-regulated TNF-induced p38 and 
p44/42 MAPK phosphorylation and nuclear translocation of 
p65 NF-κB. Evaluation of the role of Syk in lung epithelial 
cells using RNAi may help in developing new therapeutic 
tools for asthma (Ulanova, Marcet-Palacios, et al 2006).
siRNA targeting key cytokines with important roles in 
allergic asthma are expected to be of beneﬁ  t as RNAi immu-
notherapy. Other candidates considered as pharmacological 
targets for RNAi are TNF-alpha (Sorensen et al 2003) and 
the common beta-chain of the GM-CSF/IL-3/IL-5 receptor 
(Scherr et al 2003).
The safety proﬁ  le of in vivo interventions using siRNA 
has to be evaluated in the future. These short RNA molecules 
have the potential to elicit immunological effects, including 
the induction of some proinﬂ  ammatory cytokines and type I 
interferon. RNA-sensing immunoreceptors include members 
of the TLR family (TLR3, TLR7, TLR8) and cytosolic RNA-
binding proteins (PKR, helicases RIG-I and Mda5). Type I 
interferon induction by synthetic siRNA requires TLR7 and 
is sequence dependent, similar to the detection of CpG motifs 
by TLR9 (Schlee et al 2006). It is possible to administer 
naked, synthetic siRNAs in animals, without inducing an 
interferon response (Heidel et al 2004). Experts must under-
stand all aspects of such immune responses, including their 
implications for gene silencing technologies, if they want 
to minimize unwanted non-speciﬁ  c effects (Kawasaki et al 
2004). Moreover, great attention is needed while evaluating 
potential severe side effects of long-term RNAi technologies 
before using in humans (Kurreck 2003).
Antagomirs
Antagomirs are a novel class of chemically engineered oli-
gonucleotides (Krutzfeldt et al 2005), synthetic analogs of 
miRNA (Mattes et al 2007), that are powerful tools in vivo for Biologics: Targets & Therapy 2007:1(3) 281
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speciﬁ  c, efﬁ  cient and long-lasting silencing of endogenous 
miRNA, an abundant class of non-coding or non-messenger 
RNA molecules believed to have important roles in many 
biological processes through regulation of gene expression. 
Parenteral administration of antagomirs induced in mice a 
signiﬁ  cant reduction of corresponding miRNA levels in vari-
ous tissues, including the lung. In antagomir-treated animals, 
gene expression and mRNA analysis revealed that regions 
of downregulated genes are depleted in miRNA recognition 
motifs (Krutzfeldt et al 2005).
Aberrant miRNA expression has been described in some 
human malignancies (Venturini et al 2007). Understanding 
the role of miRNA in asthma pathophysiology and the use 
of antagomirs may identify new potential biological targets 
for therapeutic intervention (Mattes et al 2007).
The identiﬁ  cation of miRNA signatures was recently 
achieved in peripheral blood mononuclear cells isolated from 
a patient with asthma. Understanding the miRNA signature 
in susceptible individuals may potentially identify new drug 
targets. The future use of this new technology for the spe-
ciﬁ  c regulation of gene expression in respiratory diseases is 
awaited with enthusiasm (Mattes et al 2007).
Finally, several conclusions must be discussed. The 
deciphering of the human genome has revolutionized the 
strategy of nucleic-acid based technologies with sequences 
complementary to speciﬁ  c target genes. Promising antisense 
therapeutic strategies designed to speciﬁ  cally recognize and 
block the target mRNAs, have the potential to satisfy unmet 
needs in asthma treatment, acting at a more proximal level to 
a key patho-physiological molecular process, represented by 
abnormal expression of genes (Popescu 2005a).
Anti-mRNA approach in asthma can be achieved by 
using antisense oligonucleotides, ribozymes, and RNA 
interference (Sel et al 2006). siRNA is currently the fastest 
growing research ﬁ  eld for target validation and therapeutic 
applications. Targeting mRNA rather than the protein itself is 
a more efﬁ  cient approach to block a protein function, because 
multiple copies of a protein (approximately 5,000 copies) 
are produced by each mRNA molecule. There are several 
similar problems of effectiveness in all of these anti-mRNA 
methods: efﬁ  cient delivery, enhanced stability, minimiza-
tion or elimination of sequence- and substance-dependent 
side effects, and identiﬁ  cation of sensitive sites in the target 
mRNAs (Scherer and Rossi 2003). Priorities and standards 
in antisense research is needed.
At present, there are no systemically administered nucleic 
acid-based therapeutics approved for human use. This reﬂ  ects 
the difﬁ  culties in applying antisense agents, they are often 
nuclease sensitive and have difﬁ  culties in reaching their 
site of action. Nanotechnological strategies that improve 
the nucleic acids pharmacokinetics are recently suggested 
(Schiffelers et al 2007).
ASO are being developed for a wide array of therapeutic 
applications, while siRNA is now the gold standard method 
for analyzing gene function, and expectations for new target-
speciﬁ  c drugs are high (Schlee et al 2006).
Although new biological treatments will be probably very 
expensive, their cost-effectiveness proﬁ  le will be justiﬁ  ed 
in some patients with severe refractory asthma (Bart 2007). 
After decades of difﬁ  culties, antisense interventions are 
relatively close to fulﬁ  lling their promise as therapeutics for 
clinical use. Further research is required in order to deﬁ  ne 
an optimal strategy, because it is becoming ever clearer that 
antisense drugs can give rise to practical problems and their 
use in humans is more complicated than initially assumed. 
Despite all difﬁ  culties, antisense anti-asthma drugs are sup-
posed to become a reality in the future (Grzela et al 2004).
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